

Jesús M Fernández-Gómez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2080979/publications.pdf>

Version: 2024-02-01

58
papers

1,976
citations

430874

18
h-index

243625

44
g-index

75
all docs

75
docs citations

75
times ranked

1990
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. <i>Journal of Urology</i> , 2009, 182, 2195-2203.	0.4	480
2	Prognostic Factors in Patients with Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials. <i>European Urology</i> , 2008, 53, 992-1002.	1.9	220
3	HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL. <i>Journal of Urology</i> , 2005, 174, 1242-1247.	0.4	174
4	A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C. <i>European Urology</i> , 2007, 52, 1398-1406.	1.9	170
5	The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables. <i>European Urology</i> , 2011, 60, 423-430.	1.9	148
6	Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. <i>International Journal of Clinical Practice</i> , 2008, 62, 1076-1086.	1.7	119
7	Efficacy and safety of a hexanic extract of <i>Serenoa repens</i> (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (<sc>LUTS</sc>/<sc>BPH</sc>): systematic review and meta-analysis of randomised controlled trials and observational studies. <i>BJU International</i> . 2018. 122. 1049-1065.	2.5	69
8	Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. <i>European Urology</i> , 2015, 68, 256-262.	1.9	63
9	Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guérin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-muscle-invasive Bladder Cancer in Intermediate- and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial. <i>European Urology</i> , 2015. 67. 508-516.	1.9	54
10	Stromal factors involved in human prostate cancer development, progression and castration resistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 351-359.	2.5	41
11	Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer. <i>European Urology</i> , 2007, 51, 1267-1274.	1.9	37
12	Diagnostic Value of Anti-deamidated Gliadin Peptide IgG Antibodies for Celiac Disease in Children and IgA-deficient Patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 50-55.	1.8	37
13	Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer. <i>Journal of Urology</i> , 2010, 184, 1507-1513.	0.4	34
14	Molecular Classification of Non-muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and T1/T2 High-Grade) Using Next-Generation Sequencing. <i>Journal of Urology</i> , 2014, 191, 564-572.	2.8	24
15	Polyamine-modulated Factor-1 Methylation Predicts Bacillus Calmette-Guérin Response in Patients with High-grade Non-muscle-invasive Bladder Carcinoma. <i>European Urology</i> , 2013, 63, 364-370.	1.9	23
16	Estimulación transcutánea del nervio tibial posterior en el tratamiento de la incontinencia urinaria de urgencia refractaria, de origen idiopático y neuropático. <i>Actas Urológicas Españolas</i> , 2017, 41, 465-470.	0.7	23
17	A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness. <i>PLoS ONE</i> , 2013, 8, e53328.	2.5	22
18	Predictive Factors for Impaired Renal Function following Nephroureterectomy in Upper Urinary Tract Urothelial Cell Carcinoma. <i>Urologia Internationalis</i> , 2014, 92, 169-173.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP. <i>Actas Urológicas Españolas</i> , 2016, 40, 209-216.	0.7	18
20	Clinical Benefit of Tamsulosin and the Hexanic Extract of <i>Serenoa Repens</i> , in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2909.	2.4	16
21	Tratamientos actuales tras fracaso a BCG en cáncer de vejiga no músculo-invasivo. <i>Actas Urológicas Españolas</i> , 2021, 45, 93-102.	0.7	16
22	Sympathetic skin response in patients with erectile dysfunction. <i>BJU International</i> , 2009, 104, 1709-1712.	2.5	15
23	Peripheral neuropathy: an underdiagnosed cause of erectile dysfunction. <i>BJU International</i> , 2011, 108, 1855-1859.	2.5	15
24	Diagnóstico y tratamiento del cáncer de próstata clínicamente localizado. Adherencia a las guías clínicas en un estudio poblacional nacional "GESCAP". <i>Actas Urológicas Españolas</i> , 2017, 41, 359-367.	0.7	12
25	Efficacy and tolerability of the hexanic extract of <i>Serenoa repens</i> compared to tamsulosin in moderate-severe LUTS-BPH patients. <i>Scientific Reports</i> , 2021, 11, 19401.	3.3	11
26	Tratamiento del tumor vesical no músculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos españoles. <i>Actas Urológicas Españolas</i> , 2013, 37, 387-394.	0.7	10
27	Opciones terapéuticas y factores predictivos de recurrencia y mortalidad cáncer-específica en pacientes con tumor vesical después de trasplante renal: análisis multiinstitucional. <i>Actas Urológicas Españolas</i> , 2017, 41, 639-645.	0.7	10
28	Utilidad clínica de las biopsias aleatorias en el diagnóstico y tratamiento del tumor vesical no-músculo invasivo: revisión sistemática y metaanálisis. <i>Actas Urológicas Españolas</i> , 2018, 42, 285-298.	0.7	10
29	Significance of Collagenase 3 (Matrix Metalloproteinase 13) in Invasive Bladder Cancer: Correlation with Pathological Parameters. <i>Urologia Internationalis</i> , 2007, 78, 140-144.	1.3	8
30	Relationship between metalloprotease expression in tumour and stromal cells and aggressive behaviour in prostate carcinoma: Simultaneous high-throughput study of multiple metalloproteases and their inhibitors using tissue array analysis of radical prostatectomy samples. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 171-176.	1.4	8
31	La calidad de <i>Actas Urológicas Españolas</i> y sus revisores. <i>Actas Urológicas Españolas</i> , 2016, 40, 595-596.	0.7	6
32	Telomere Length on Bladder Washing Samples from Patients with Bladder Cancer Correlates with Tumor Characteristics. <i>European Urology</i> , 2005, 48, 432-437.	1.9	5
33	Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo. <i>Actas Urológicas Españolas</i> , 2018, 42, 73-76.	0.7	5
34	Efficacy and Safety of the Hexanic Extract of <i>Serenoa repens</i> vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 967.	2.4	5
35	Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata. <i>Actas Urológicas Españolas</i> , 2020, 44, 156-163.	0.7	4
36	Metaloproteína 11, potencial marcador y diana molecular en cáncer de próstata avanzado y resistente a la castración. Estudio en cultivo de fibroblastos peritumorales. <i>Actas Urológicas Españolas</i> , 2017, 41, 376-382.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Análisis comparativo de la expresión de metaloproteasas (MMP-2, MMP-9, MMP-11 y MMP-13) y del inhibidor tisular de la metaloproteasa 3 (TIMP-3) entre las biopsias previas negativas y las prostatectomías radicales. <i>Actas Urológicas Españolas</i> , 2020, 44, 78-85.	0.7	3
38	A new form of presentation of renal actinomycosis: renal tumor with retroperitoneal bleeding. <i>Archivos Espanoles De Urologia</i> , 2006, 59, 756-9.	0.2	3
39	Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of <i>Serenoa repens</i> versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3615.	2.4	3
40	GnRH antagonist administration to postpone a weekend intrauterine insemination: a large cohort study from a public center. <i>Reproductive Biology and Endocrinology</i> , 2016, 14, 53.	3.3	1
41	Duplicación ciega ureteral asociada a carcinoma transicional de vejiga. <i>Actas Urológicas Españolas</i> , 2003, 27, 568.	0.7	0
42	Determination of a New Cut-Off Value for the Urinary BTAtrak to Optimize the Detection of Recurrences in the Follow-Up of Patients with Superficial Bladder Carcinoma. <i>Current Urology</i> , 2007, 1, 42-47.	0.6	0
43	594 FACTORS AFFECTING TUMOR RECURRENCE AND PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER (TA, T1, TIS) TREATED WITH BACILLUS CALMETTE-GUÉRIN. MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMIZED CUETO TRIALS. <i>European Urology Supplements</i> , 2007, 6, 171.	0.1	0
44	MO45 Peripheral large fiber neuropathy in patients with erectile dysfunction. <i>Clinical Neurophysiology</i> , 2008, 119, S42.	1.5	0
45	PREDICTION OF RECURRENCE AND PROGRESSION OF NON- MUSCLE INVASIVE BLADDER CANCER IN PATIENTS TREATED WITH BACILLUS CALMETTE-GUÉRIN: A SCORING SYSTEM BASED ON MULTIVARIATE ANALYSIS OF DATA FROM FOUR RANDOMISED CUETO TRIALS. <i>European Urology Supplements</i> , 2008, 7, 298.	0.1	0
46	Retroperitoneal residual mass resection: retroaortic renal vein. <i>Actas Urológicas Españolas (English)</i> 10, 2007, 10, 0.	0.2	0
47	656 RANDOMIZED PHASE III TRIAL COMPARING ADJUVANT PACLITAXEL/GEMCITABINE/CISPLATIN (PGC) TO OBSERVATION IN PATIENTS WITH RESECTED INVASIVE BLADDER CANCER: RESULTS OF THE SOGUG-GUO-AEU 99/01 TRIAL. <i>European Urology Supplements</i> , 2011, 10, 212.	0.1	0
48	1875 METHYLATION OF TUMOR SUPPRESSOR GENES PREDICT RECURRENCE AND SUBCLASSIFY NON MUSCLE-INVASIVE DISEASE: PTA LOW GRADE VERSUS PT1 LOW GRADE AND PT1 HIGH GRADE BLADDER TUMORS. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
49	Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. <i>International Journal of Urology</i> , 2015, 22, 548-548.	1.0	0
50	Editorial Comment to Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. <i>International Journal of Urology</i> , 2015, 22, 548-548.	1.0	0
51	Los revisores de <i>Actas Urológicas Españolas</i> . Un privilegio para nuestra urología. <i>Actas Urológicas Españolas</i> , 2015, 39, 595-596.	0.7	0
52	MP29-01 TREATMENT OPTIONS AND PREDICTIVE FACTORS FOR RECURRENCE AND CANCER SPECIFIC MORTALITY IN BLADDER CANCER AFTER RENAL TRANSPLANTATION: A MULTIINSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
53	Beneficio de la nefrectomía en el tratamiento del carcinoma de células renales metastásico. <i>Actas Urológicas Españolas</i> , 2017, 41, 338-342.	0.7	0
54	Agradecimiento a los revisores de <i>Actas Urológicas Españolas</i> . <i>Actas Urológicas Españolas</i> , 2017, 41, 605-606.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Revisión de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urología. Documento de consenso entre la Asociación Española de Urología y la Sociedad Española de Farmacia Hospitalaria. Actas Urológicas Españolas, 2018, 42, 375-380.	0.7	0
56	La consolidación de Actas Urológicas Españolas. Actas Urológicas Españolas, 2018, 42, 423-424.	0.7	0
57	Utilidad de la PET/TC 18-FDG en diagnóstico y seguimiento de tumores urológicos uroteliales y renales. Actas Urológicas Españolas, 2019, 43, 32-38.	0.7	0
58	Review of evidence on handling hazardous drugs and Products in Urology Services; consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists. Farmacia Hospitalaria, 2018, 42, 212-215.	0.6	0